The main purpose of this study is to compare the amount of LY3871801 that gets into the blood stream and how long it takes the body to get rid of it, when given as crystalline freebase tablet (test) and as a solid dispersion oral suspension (reference) in healthy participants. The information about any adverse effects experienced will be collected and the tolerability of LY3871801 will also be evaluated. The study may last up to approximately 15 days excluding the 28 days of screening period.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
15
Administered orally.
Lilly Centre for Clinical Pharmacology
Singapore, Singapore
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3871801
PK: Cmax of LY3871801
Time frame: Predose through Day 4
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3871801
PK: AUC\[0-∞\] of LY3871801
Time frame: Predose through Day 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.